Poolbeg Pharma PLC (AIM:POLB, OTC:POLBF, FRA:POLBF) CEO Jeremy Skillington and principal scientist Liam Tremble joined Proactive's Stephen Gunnion to discuss a pivotal moment for the company's lead asset, POLB 001.
Full MHRA clearance has been secured, clearing the final regulatory hurdle before patient screening begins across six UK sites. Interim data from the trial, which targets cytokine release syndrome — a serious complication of cancer immunotherapies — is expected this summer.
On the commercial side, independent US payer research confirms multi-billion-dollar peak sales potential, with insurers recognising the significant cost burden CRS places on healthcare systems. The findings are expected to strengthen Poolbeg's hand in upcoming partnership discussions.
For more videos like this, visit Proactive’s YouTube channel, like this video, subscribe, and enable notifications so you never miss an update.
#PoolbegPharma #POLB001 #Biotech #ClinicalTrials #CRS #PharmaNews #DrugDevelopment #HealthcareInnovation #Investing #Biopharma #MHRA #CytokineReleaseSyndrome #LifeSciences
